Skip to main content
. 2018 Feb 13;39(4):1631–1639. doi: 10.3892/or.2018.6268

Figure 1.

Figure 1.

miR-181 expression in patients with cisplatin-induced NSCLC. Control, paracarcinoma tissue group; cisplatin-NSCLC, cisplatin-resistant NSCLC. ##p<0.01 vs. paracarcinoma tissue group. NSCLC, non-small-cell lung cancer.